Rosen Law Firm Encourages Nektar Therapeutics Investors to Secure Counsel Before Deadline

Investors who purchased Nektar securities during the Class Period may be entitled to compensation.

Apr. 6, 2026 at 11:30pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of legal documents, a gavel, and a calculator arranged on a clean white background, conceptually representing the legal process and financial stakes involved in a securities class action lawsuit.A legal case against a pharmaceutical company aims to protect the rights and investments of its shareholders.NYC Today

Rosen Law Firm, a global investor rights law firm, is reminding purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025 of the important May 5, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Nektar made false and/or misleading statements about enrollment issues and the integrity of its REZOLVE-AA trial.

Why it matters

This case highlights the importance of investor protections and the role of class action lawsuits in holding public companies accountable for alleged misconduct that can impact shareholder value. The Rosen Law Firm has a track record of success in securities class actions, making it an experienced counsel option for Nektar investors.

The details

According to the lawsuit, Nektar is accused of making false and/or misleading statements about issues with the enrollment and protocol standards of its REZOLVE-AA trial. The lawsuit claims these issues were likely to have a significant negative impact on the trial's results, overstating the overall integrity and prospects of the trial. Investors who purchased Nektar securities during the Class Period may be entitled to compensation through the class action lawsuit.

  • The Class Period is from February 26, 2025 to December 15, 2025.
  • The lead plaintiff deadline is May 5, 2026.

The players

Rosen Law Firm

A global investor rights law firm that is representing investors in the Nektar Therapeutics securities class action lawsuit.

Nektar Therapeutics

A biopharmaceutical company that is the defendant in the securities class action lawsuit.

Got photos? Submit your photos here. ›

What they’re saying

“To join the Nektar class action, go to https://rosenlegal.com/submit-form/?case_id=55599 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.”

— Phillip Kim, Esq.

What’s next

Investors who purchased Nektar securities during the Class Period have until May 5, 2026 to move the Court to serve as lead plaintiff in the class action lawsuit.

The takeaway

This case underscores the importance of investor protections and the role of class actions in holding public companies accountable for alleged misconduct that can impact shareholder value. Experienced counsel like the Rosen Law Firm can help investors navigate the process of joining the Nektar class action lawsuit.